Search & Analyze

Cohance Lifesciences Ltd.

444.45−36.90 (−7.67%)

BSE · 30 Oct, 4:01 PM

: ₹17,004.54 Cr
: 160.07
: 1,11,744
: ₹480.60 - ₹442.00
: ₹761.60 - ₹267.85

Cohance Lifesciences Ltd. (COHANCE) share price closed at ₹444.45 on the BSE on Friday, October 30, 2026, down by 7.67% from its of ₹481.35. In that session COHANCE reached a of 480.60 and of 442.00. The for the session was 453.46. The stands at 453.11 and is at 409.58. Looking at , the stock ended the session in Downtrend.

Stock Overview

₹479.95

₹481.35

₹453.46

₹453.11

Price 1.91% below

₹409.58

Price 8.51% above

Key Fundamentals

: 17,004.54 Cr₹17.00 Thousand Crore
: 2.78
: 160.07
: 4.42
: 100.60
: 348.31 Cr₹348.31 Crore
: 0.00 %
Sector
Industry: Pharmaceuticals & Drugs
: 4.02
: 0.04

Industry Comparison

Ratio	Company	Sector
	160.07	44.77
	0.04	0.20
	4.42	4.61
	2.78	1.81
	0.00 %	0.11 %
Operating Margin	18.82 %	19.15 %

Sector figures are the median of 154 listed Healthcare companies.

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,778.25	38.91	4,26,661.74	0.90	1,995.07	-36.16%	16,198.71	11.88%	19.11
DIVI'S LAB. DIVISLAB	9,715.00	88.17	2,57,902.73	0.31	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,635.15	83.01	1,76,306.21	0.82	534.00	-9.64%	4,979.00	50.79%	19.27
LAURUSLABS LAURUSLABS	2,392.00	96.46	1,29,242.68	0.08	436.19	124.27%	2,206.37	33.44%	18.20
ZYDUSLIFE ZYDUSLIFE	1,244.00	27.50	1,24,089.48	0.08	990.20	-34.90%	8,017.00	21.96%	21.39
DR.REDDY'S DRREDDY	1,350.20	40.25	1,12,698.53	0.59	913.20	-31.69%	8,697.80	-1.48%	13.75
CIPLA LTD. CIPLA	1,380.00	38.48	1,11,488.55	0.94	851.51	-37.08%	7,403.93	-2.44%	16.00
Cohance Lifesciences Ltd. COHANCE	444.45	160.07	17,004.54	0.00	-45.19	-197.39%	422.26	-23.13%	6.12

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	252.93	488.08	603.77	676.23	840.42	549.31	555.57	544.55	619.12	422.26
Expenses	179.59	362.98	398.40	438.86	611.20	437.30	434.62	449.20	520.44	421.10
	73.34	125.10	205.37	237.37	229.22	112.01	120.95	95.35	98.68	1.16
	29.00%	25.63%	34.01%	35.10%	27.27%	20.39%	21.77%	17.51%	15.94%	0.27%
	17.06	19.41	16.19	21.56	-3.73	6.07	15.60	1.30	-18.35	12.25
Interest	2.30	10.20	9.61	10.80	10.45	10.18	8.76	9.11	9.19	6.74
	17.25	31.28	37.79	43.56	54.17	45.14	44.02	46.94	51.23	49.54
	70.85	103.03	174.16	204.57	160.87	62.76	83.77	40.60	19.91	-42.87
	24.67%	26.85%	20.62%	24.97%	27.18%	26.07%	20.75%	28.52%	58.26%	-5.41%
	53.37	75.37	138.47	153.07	120.43	48.88	74.08	36.72	19.55	-24.12
	2.10	2.96	5.44	6.01	4.73	1.28	1.94	0.96	0.51	-0.63

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	1,321.12	1,341.49	1,051.35	2,608.50	2,268.55
	1,320.22	1,340.33	1,051.35	2,608.50	2,268.55
EXPENDITURE :
Increase/Decrease in Stock	-60.35	-20.94	49.16	106.42	-42.76
Raw Material Consumed	454.40	423.91	262.70	707.37	699.92
Power & Fuel Cost	59.55	73.93	48.30	107.49	122.51
Employee Cost	100.48	118.25	135.23	447.81	507.71
Other Manufacturing Expenses	129.24	109.62	88.37	215.67	285.60
General and Administration Expenses	28.99	33.87	27.11	93.37	148.72
Selling and Distribution Expenses	19.80	17.64	10.46	42.72	53.80
Miscellaneous Expenses	6.37	9.90	24.21	90.59	66.06
	738.50	766.17	645.54	1,811.44	1,841.56
Operating Profit (Excl OI)	581.72	574.16	405.81	797.06	426.99
	92.38	46.36	61.91	69.21	34.09
	674.10	620.53	467.72	866.27	461.08
Interest	8.53	12.81	7.45	41.06	37.24
PBDT	665.57	607.72	460.27	825.21	423.84
	39.10	47.99	54.60	166.80	187.33
Profit Before Taxation & Exceptional Items	626.48	559.73	405.67	658.41	236.51
Exceptional Income / Expenses				-15.78	-29.47
	667.59	559.73	405.67	642.63	207.04
Provision for Tax	213.78	148.44	105.39	158.39	56.92
	453.80	411.29	300.28	484.24	150.12
Extra items				0.00	0.00
Minority Interest				3.10	29.11
Consolidated Net Profit	453.80	411.29	300.28	487.34	179.23
Profit Balance B/F	936.49	1,272.71	1,465.16	2,246.16	2,084.25
Appropriations	1,390.30	1,684.00	1,765.44	2,733.50	2,263.48
Equity Dividend %	500.00%	600.00%
	17.83	16.16	11.79	19.14	4.68
Adjusted EPS	17.83	16.16	11.79	19.14	4.68

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	25.46	25.46	25.46	25.46	38.26
Share Warrants & Outstandings			1.97	81.78	18.08
Total Reserves	1,501.72	1,709.73	2,023.24	3,541.58	3,854.95
Reserve excluding Revaluation Reserve	1,501.72	1,709.73	2,023.24	3,541.58	3,854.95
Revaluation reserve				0.00
	1,527.18	1,735.18	2,050.67	3,648.82	3,911.29
Minority Interest				144.06	122.54
Secured Loans	28.44	4.56		129.75	50.48
Deferred Tax Assets / Liabilities	54.32	58.23	64.79	102.04	95.26
Other Long Term Liabilities	0.46	0.70	21.24	750.07	901.10
Long Term Provisions	8.89	8.30		0.26	0.40
Total Non-Current Liabilities	92.11	71.79	86.03	982.12	1,047.24
Trade Payables	105.90	70.09	42.35	268.43	284.58
Other Current Liabilities	29.54	19.84	21.23	313.25	223.19
Short Term Borrowings	67.13	64.60	38.58	70.65	74.43
Short Term Provisions	144.94	148.56	15.24	53.08	63.73
Total Current Liabilities	347.52	303.09	117.40	705.41	645.93
Total Liabilities	1,966.81	2,110.07	2,254.10	5,480.41	5,727.00
Gross Block	693.81	875.60	929.16	3,788.42	4,230.69
Less: Accumulated Depreciation	159.62	212.27	259.54	681.13	861.95
	534.19	663.33	669.62	3,107.29	3,368.74
	29.99	165.09	178.97	331.60	173.22
Non Current Investments	117.10	117.10	130.58	145.42	262.23
Long Term Investment	117.10	117.10	130.58	145.42	262.23
Long Term Loans & Advances	13.07	9.19	21.61	86.45	71.47
Other Non Current Assets	7.30			13.35	18.87
Total Non-Current Assets	701.66	954.70	1,000.89	3,686.93	3,899.04
Currents Investments	481.22	418.94	773.90	191.74	266.32
Inventories	283.42	312.81	231.20	467.37	562.23
Sundry Debtors	236.37	110.94	133.66	772.10	681.01
Cash and Bank	47.31	68.01	50.50	102.48	59.66
Other Current Assets	10.87	11.46	11.90	32.66	41.74
Short Term Loans and Advances	205.97	233.21	52.05	191.82	185.30
Total Current Assets	1,265.16	1,155.37	1,253.21	1,758.17	1,796.26
Net Current Assets (Including Current Investments)	917.64	852.28	1,135.81	1,052.76	1,150.33
Total Assets	1,966.81	2,110.07	2,254.10	5,480.41	5,727.00
	6.07	6.07	18.11	57.92	53.31
Total Debt	95.57	69.16	38.58	258.36	169.67
	59.99	68.16	80.47	140.10	101.76
Adjusted Book Value	59.99	68.16	80.47	140.10	101.76

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	667.59	559.73	405.67	642.63	207.04
Adjustment	40.63	37.46	17.14	207.36	208.29
Changes In working Capital	-193.97	5.77	71.91	-0.73	20.76
Cash Flow after changes in Working Capital	514.26	602.96	494.72	849.26	436.09
Cash Flow from Operating Activities	330.00	457.20	384.77	673.35	368.32
Cash Flow from Investing Activities	-136.14	-195.01	-362.35	-389.70	-254.57
Cash Flow from Financing Activitie	-156.48	-241.95	-39.99	-327.40	-165.15
Net Cash Inflow / Outflow	37.38	20.24	-17.57	-43.75	-51.40
Opening Cash & Cash Equivalents	7.18	44.56	64.80	138.32	96.65
Effect of Foreign Exchange Fluctuations	0.00			2.08	3.89
Closing Cash & Cash Equivalent	44.56	64.80	47.23	96.65	49.14

Ratios

Valuation

160.07

4.42

49.14

7.94

2.78

100.60

Profitability

4.02

6.12

2.68

18.82

6.62

Leverage & Liquidity

0.04

2.78

6.56

Returns

0.00

0.40

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26	Sep '26
	50.10	50.10	50.10	50.10	66.41	57.49	57.49	57.49	57.49	57.48
	27.23	27.65	27.53	27.66	18.64	27.34	27.60	27.39	26.60	26.57
	22.67	22.25	22.37	22.23	14.95	15.17	14.92	15.12	15.92	15.95
	49.90	49.90	49.90	49.90	33.59	42.51	42.51	42.51	42.51	42.52
No. of Shareholders	65,777	69,337	84,210	86,325	80,910	75,284	81,877	85,230	99,149	93,846

Mutual Funds Invested(107)

Based on each fund's latest monthly portfolio · Sep 2026

A total of 59 active funds hold 16.65% in Cohance Lifesciences Ltd., contributing to ₹2.83K Cr of holdings

Fund				As of
IP ICICI Prudential Healthcare Fund - Growth - Direct PlanPharma & Health Care	278.24	4.06	62,66,692	Sep '26
SB SBI Multi Asset Allocation Fund - Growth - Direct PlanHybrid - Multi Asset Allocation	230.88	1.10	52,00,000	Sep '26
IN Invesco India Contra Fund - Growth - Direct PlanEquity - Contra Fund	195.08	1.01	43,93,667	Sep '26
HD HDFC Balanced Advantage Fund - Growth - Direct PlanHybrid - Balanced Advantage	183.97	0.18	41,43,548	Sep '26
DS DSP Healthcare Fund - Growth - Direct PlanPharma & Health Care	142.21	3.79	32,02,999	Sep '26
ID Bandhan Small Cap Fund - Growth - Direct PlanSmall cap Fund	138.87	0.39	31,27,757	Sep '26
SB SBI Balanced Advantage Fund - Growth - Direct PlanHybrid - Balanced Advantage	133.20	0.33	30,00,000	Sep '26
DS DSP Aggressive Hybrid Fund - Growth - Direct PlanHybrid - Aggressive Hybrid Fund	104.22	0.92	23,47,265	Sep '26
SB SBI MNC Fund - Growth - Direct PlanMNC	97.68	1.53	22,00,000	Sep '26
SB SBI Healthcare Opportunities Fund - Growth - Direct PlanPharma & Health Care	97.68	1.66	22,00,000	Sep '26

Corporate Actions

Showing: All

Date	Type	Details
2026-10-26	Board Meeting	Quarterly Results
2026-08-21	AGM
2026-07-23	Board Meeting	Quarterly Results

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Cohance Lifesciences Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

12 members across the board and senior leadership

Umang Vohra

Chairman & Group CEO

—

Matangi Gowrishankar

Non Executive Independent Director

₹30.00 L

Mar '26

Himanshu Agarwal

Whole Time Director

—

Vinod Rao

Non Executive Independent Director

₹30.00 L

Mar '26

K G Ananthakrishnan

Non Executive Independent Director

₹30.00 L

Mar '26

UB Pravin Rao

Non Executive Independent Director

₹30.00 L

Mar '26

Jai Shankar Krishnan

Non Executive Independent Director

₹30.00 L

Mar '26

Shweta Jalan

Non Executive Director

—

Pankaj Patwari

Non Executive Director

—

Vinod Padikkal

Non Executive Director

—

KG Ananthakrishnan

Non Executive Independent Director

₹30.00 L

Mar '25

Sisir K Mishra

Company Secretary & Compliance Officer

—

COHANCE Latest News

News

10 of 10 articles

EQUITY6 Oct 2026 · 16:32

Cohance Lifesciences informs about ESG rating

EQUITY21 Sept 2026 · 16:12

Cohance Lifesciences informs about update

COMPANY21 Sept 2026 · 12:17

USFDA concludes inspection at Cohance Lifesciences’ Andhra Pradesh facility

The inspection concluded with the issuance of a Form FDA 483 containing five observations

EQUITY17 Sept 2026 · 15:36

Cohance Lifesciences submits analyst meet intimation

COMPANY7 Sept 2026 · 10:28

Cohance Lifesciences receives four observations from USFDA for Telangana FDF plant

The USFDA conducted an inspection of the said plant from August 27 to September 4, 2026

EQUITY12 Aug 2026 · 14:50

Cohance Lifesciences informs about disclosure

COMPANY6 Aug 2026 · 12:41

Cohance Lifesciences receives five observations from USFDA for Pashamylaram facility

USFDA has conducted an inspection from July 27, 2026, to August 5, 2026 at the said facility

EQUITY19 Jun 2026 · 14:55

Cohance Lifesciences informs about disclosures

EQUITY19 Jun 2026 · 11:43

Cohance Lifesciences informs about disclosure

EQUITY18 Jun 2026 · 17:23

Cohance Lifesciences informs about disclosure

Cohance Lifesciences Ltd.

Stock Overview

Price chart

Peer Comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Valuation

Profitability

Leverage & Liquidity

Returns

Shareholding Pattern

Mutual Funds Invested(107)

Corporate Actions

Insider Trading

Sector Overview

Company Profile

Key Management

COHANCE Latest News

News